Dba: Village Visions Optometrist Medicare: Medicare Enrolled Practice Location: 3986 Jordan Rd, Skaneateles, NY 13152 Phone: 315-685-2020 Fax: 315-685-3337 |
Dr. Casimir Karol Bobowski, OD Optometrist Medicare: Medicare Enrolled Practice Location: 1342 New Seneca Tpke, Skaneateles, NY 13152 Phone: 315-685-6185 Fax: 315-685-2235 |
Dr. John J Maurillo Jr., O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 3986 Jordan Rd, Suite A, Skaneateles, NY 13152 Phone: 315-685-2020 Fax: 315-685-3337 |
News Archive
Bisphenol A (BPA), an estrogen-like compound that has drawn increased scrutiny in recent years, has been linked to changes in thyroid hormone levels in pregnant women and newborn boys, according to a new study by researchers at the University of California, Berkeley.
Dove Medical Press, a leading open-access publisher, has entered into an alliance with Athena Healthcare Consultancy, a well established CRO and pharmaceutical medical marketing consultancy based in Shanghai.
Two research units under Singapore's Agency for Science, Technology and Research (A*STAR), the Experimental Therapeutics Centre (ETC) and Singapore Immunology Network (SIgN), are collaborating with Italy's Siena Biotech S.p.A. to develop new drugs and targeted antibodies respectively, which will potentially help millions of cancer and bone loss patients across the world. This is the fifth major collaboration A*STAR has with research centres and universities in Italy .
Although some civil rights groups that are "pressing" the North Carolina Legislature to pass a bill that would mandate HIV testing for prison inmates might be overstating HIV prevalence in prisons, their "point shouldn't be missed" because the "fact is, consensual and forced sex behind bars ... helps spread the disease," a Raleigh News & Observer editorial says.
RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced the unblinded results of the first of their 2 placebo-controlled double blind studies in volunteers with their anti-scarring agent RXI-109, a proprietary sd-rxRNA compound that has been shown in vitro and in animals to reduce mRNA for connective tissue growth factor.
› Verified 7 days ago